TenNor Therapeutics’ Rifasutenizol Shows High Eradication Rate in H. pylori Phase III Study
China-based TenNor Therapeutics has announced positive results from its Phase III clinical study for rifasutenizol...
Beijing Wantai Receives NMPA Clearance for Nine-Valent HPV Vaccine Targeting Male Population
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd (SHA: 603392), a leading Chinese pharmaceutical company, has...
Hasten Biopharmaceutical Initiates Phase III Clinical Trial for Lerodalcibep in China
China-based Hasten Biopharmaceutical Co., Ltd, a comprehensive biopharmaceutical company co-established by CBC Group, has announced...
VelaVigo and Avenzo Therapeutics Ink Global Partnership for Nectin4/TROP2 Bispecific ADC
Shanghai-based biotech company VelaVigo, specializing in bispecific/multi-specific antibodies and antibody drug conjugates (ADCs), has announced...
Youjia Biomedical and Yiling Pharmaceutical Collaborate on RNAi Metabolic Disease Treatments
China-based Youjia (Hangzhou) Biomedical Technology Co., Ltd, a leading nucleic acid technology developer, has entered...
Grand Pharmaceutical Group Expands Distribution Partnership with Sirtex Medical in China
Grand Pharmaceutical Group Ltd (HKG: 0512), a leading pharmaceutical company based in China, has announced...
Keymed Biosciences Enters Global Licensing Agreement with Platina Medicines for CM336
Keymed Biosciences Inc., a China-based biopharmaceutical company (HKG: 2162), has announced a significant licensing agreement...
CanSino Biologics Initiates Phase I Clinical Trial for Freeze-Dried Hib Conjugate Vaccine
China-based biopharmaceutical company CanSino Biologics (HKG: 6185) has announced the commencement of a Phase I...
Hangzhou Jiuyuan Gene Engineering Passes HKEX IPO Hearing for Orthopedic Treatments
Hangzhou Jiuyuan Gene Engineering Co., Ltd. has announced that it has successfully passed the listing...
NK CellTech Partners with 3SBio to Advance NK Cell Therapy Technology
China-based natural killer (NK) cell therapy developer NK CellTech has entered into a strategic partnership...
Shanghai’s Matwings Secures Over $13.8 Million in Series A Financing for AI Protein Design
Matwings, an AI-based protein design service provider headquartered in Shanghai, has announced the successful completion...
EMA’s CHMP Recommends Approval for MSD’s Keytruda Combo in Mesothelioma Treatment
Merck, Sharp & Dohme Inc., (MSD; NYSE: MRK), a leading US pharmaceutical company, has announced...
EMA’s CHMP Recommends Approval for BMS’s Opdivo/Yervoy Combo in mCRC
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...
Boston Scientific Expands Neuromodulation Portfolio with Axonics Acquisition
Boston Scientific Corporation (NYSE: BSX), a leading player in the medical device industry, has announced...
Sandoz Receives EC Approval for Biosimilar to Eylea for Retinal Diseases
Switzerland-based pharmaceutical company Sandoz (SWX: SDZ) has announced that it has received marketing approval from...
Peijia Medical Achieves First Compassionate Use of Taurus Trio TAVR System in Hong Kong
Peijia Medical Ltd (HKG: 9996), a leading medical device company, has announced the completion of...
Sanofi’s Dupixent sBLA for Chronic Spontaneous Urticaria Accepted by FDA for Review
French pharmaceutical giant Sanofi has announced that the US Food and Drug Administration (FDA) has...
Novo Nordisk Launches Semaglutide for Weight Management in China
Denmark-based healthcare giant Novo Nordisk A/S (NYSE: NVO) has announced the official market launch of...
Sichuan Kelun-Biotech Secures NMPA Approval for Two Antibody Drug Conjugates
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990), a leading biopharmaceutical company based in China, has...
Exegenesis Bio’s Gene Therapy EXG110 Earns Orphan Drug Status for Fabry Disease
Exegenesis Bio, a leading provider of epigenetics experimental and analytical services headquartered in Hangzhou, has...